EVALUATION OF THE EFFICIENCY OF HEMOSTATIC THERAPY WITH MICRONIZED PROGESTERONE FOR ABNORMAL UTERINE BLEEDING

Objective. To evaluate the efficiency of different micronized progesterone regimens and administration routes for abnormal uterine bleeding. Material and methods. The investigation covered 40 women aged 18 to 45 years (mean age, 38.5±5.3 years) with moderate chronic and acute abnormal uterine bleeding. Results. Visit 1 encompassed the inclusion of the patients into the investigation, history data collection, and clinical examination. Symptomatic therapy with tranexamic acid in a dose of 250 mg thrice daily for 3 days was prescribed for hemostasis. At Visit 2, the efficiency of the symptomatic therapy with tranexamic acid was evaluated and the patients were randomized. Visit 3 was made 3 days after the initiation of treatment with the micronized progesterone pragisan (gel or capsules); the therapy efficiency was inadequate, the administration route and therapy duration were changed. Ten days after Visit 3, there was final Visit 4 at which the therapeutic effectiveness was evaluated and control ultrasonography of small pelvic organs was conducted. Conclusion. The investigations suggest that the micronized progesterone pragisan is highly hemostatic effective in 18-45-year-old patients with abnormal uterine bleeding.

abnormal uterine bleeding, hemostasis, micronized progesterone